RE:RE:Biogen CEO Resigns!! Biogen is double-dipping into a 2020 collaboration with Scribe Therapeutics, exercising its option for an additional neurological disease target in gene therapy using the biotech's CRISPR technology.
The announcement adds a second target to the partnership first disclosed in 2020 to develop a new therapy for amyotrophic lateral sclerosis (ALS). That deal included $15 million in upfront cash for Scribe with the potential for more than $400 million in milestone payments later on.
Biogen and Scribe did not disclose the new target that will be explored in the re-upped agreement nor whether exercising this option triggered additional milestone payments for Scribe. A spokesperson for Biogen declined to disclose further financial details.